New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:55 EDTAEGR, AEGR, TEVA, TEVA, DNDN, DNDN, CELG, CELG, BMRN, BMRN, ALXN, ALXN, BMY, BMY, MYL, MYL, MEIP, MEIP, ISIS, ISIS, GSK, GSK, FMI, FMI, CNAT, CNAT, BLUE, BLUE, XOMA, XOMACowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 4 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For AEGR;BLUE;CNAT;FMI;GSK;ISIS;MEIP;MYL;BMY;ALXN;BMRN;CELG;DNDN;TEVA;XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 13, 2015
17:33 EDTCELGS&P announces changes to S&P 100 Index
Subscribe for More Information
11:19 EDTBMRNBioMarin rallies amid positive call on DMD drug timeline, takeover rumor
The shares of drug maker BioMarin (BMRN) are climbing after research firm Jefferies quoted a regulatory expert as saying that the company's drisapersen drug has a good chance of being approved on an accelerated basis by the FDA. Drisapersen is a treatment for Duchenne Muscular Dystrophy, or DMD. WHAT'S NEW: "There is a strong possibility" that the FDA will grant accelerated approval to drisapersen because there is currently no approved drug for the treatment of DMD, Jefferies analyst Eun Yang quoted the expert as saying. The expert is also optimistic about the outlook for accelerated approval because she had a good experience working with BioMarin while she was with the FDA and because BioMarin has a favorable track record with the FDA, according to Yang. There is a 60% chance that drisapersen will be approved by the end of this year and the stock can rise to $155, versus its current level of about $121.50, if that does occur, the analyst stated. Yang's price target on the stock increased to $135 from $125 and the analyst kept a Buy rating on the shares. WHAT'S NOTABLE: Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash, British newspaper Daily Mail reported. , Piper Jaffray analyst Joshua Schimmer wrote in a note to investors this morning that BioMarin, along with Vertex (VRTX) and Incyte (INCY), have a "clear path" to joining the group of companies with market caps of over $10B projected to deliver greater than 20% EPS CAGR, which the analyst identified as a set of criteria that has previously pointed to companies that make good potential takeover targets. PRICE ACTION: In mid-morning trading, BioMarin climbed nearly 4% to $120.
10:51 EDTTEVA, MYLOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
10:09 EDTBMRNHigh option volume stocks
High option volume stocks: ULTA HOG CTIC CTL LOCO IMPV BMRN IMOS ATHX GALE
09:49 EDTFMIUBS life science tools/diagnostics analyst has analyst/industry conference call
Subscribe for More Information
08:07 EDTBMRNAstraZeneca rumored to have BioMarin 'on shopping list,' Daily Mail says
Subscribe for More Information
07:39 EDTBMRNBioMarin price target raised to $135 from $125 at Jefferies
Jefferies raised its price target for BioMarin shares to $135 after a regulatory expert it spoke to expressed optimism regarding drisapersen winning accelerated approval. Jefferies sees greater than 30% upside to current share levels should drisapersen get approved by the end of 2015. The firm views BioMarin as well positioned for "meaningful" long-term growth and keeps a Buy rating on the name.
05:56 EDTMYLStocks with implied volatility movement; MYL PBR
Subscribe for More Information
05:47 EDTTEVAStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
March 12, 2015
16:01 EDTTEVAOptions Update; March 12, 2015
Subscribe for More Information
15:02 EDTBMYBristol-Myers announces FDA acceptance of NDA for daclatasvir
Bristol-Myers Squibb Company announced that the resubmitted new drug application, or NDA, for daclatasvir, an investigational NS5A replication complex inhibitor, has been accepted for review by the FDA for use in combination with sofosbuvir for the treatment of chronic hepatitis C, or HCV, genotype 3. The original NDA has been amended to include data from the Phase III ALLY-3 trial, which showed high cure rates for the combination, with sustained virologic response 12 weeks after treatment in 90% of treatment-na´ve and 86% of treatment-experienced genotype 3 HCV patients. SVR12 rates were higher in non-cirrhotic genotype 3 patients, regardless of treatment history. The FDA will now review the submission within a six-month timeframe.
13:18 EDTXOMAXOMA upgraded to Buy from Neutral at Ladenburg
Subscribe for More Information
12:49 EDTBMY, TEVAWHO recommends tenofovir or entecavir for hepatitis B treatment
The World Health Organization issued its first-ever guidance for the treatment of chronic hepatitis B. Its recommended medicines consist of Gilead's (GILD) tenofovir or Bristol-Myers' (BMY) entecavir. Teva (TEVA) has FDA approval for generic entecavir.
11:38 EDTTEVATeva volatility increases on share price rally
Subscribe for More Information
11:21 EDTGSKGlaxoSmithKline to sell half of Aspen Pharmacare stake
GlaxoSmithKline announces that it intends to sell approximately half of its 12.4% stake in Aspen Pharmacare. The disposal will be through a placing of ordinary shares in Aspen to institutional investors. The offering is expected to comprise 28.2M Aspen ordinary shares. After the proposed transaction, GSK would remain a 6.2% shareholder in Aspen and has undertaken not to dispose of any shares in Aspen for a period of 180 days following completion, subject to certain limited exceptions. GSK has entered into a placing agreement with Citigroup Global Markets Limited and UBS Limited to act as the Joint Bookrunners in relation to the Offering. Proceeds from the transaction will be used for general corporate purposes, GSK said. The net profit on disposal will not be included in core operating profit and core EPS in 2015 and it is expected that GSK will no longer account for Aspen as an associate going forward.
11:14 EDTTEVAPiper Jaffray biopharm analyst analyst/industry conference call at 12 pm
***TIME CHANGED TO 12pm from 11am on March 12***Biopharmaceuticals Analyst Schimmer, along with Dr. Bianca Weinstock-Guttman, discuss the current and future treatment paradigm and practice dynamics in MS on an Analyst/Industry conference call to be held on March 12.
10:20 EDTCELGCelgene management to meet with Piper Jaffray
Subscribe for More Information
10:06 EDTMEIPHigh option volume stocks
Subscribe for More Information
08:09 EDTTEVA, MYLTeva Mylan combination problematic for now, says Bernstein
Subscribe for More Information
05:55 EDTTEVAStocks with implied volatility movement; TEVA VRX
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use